Nasdaq

Moderna Files FDA Application for the JN.1 Targeting COVID-19 Vaccine

Manufacturing is underway and doses of Moderna's Spikevax 2024-2025 formula will be ready to ship as early as August, pending regulatory approval The most common solicited local adverse event for ...
KTVU

Pfizer starts application for full FDA approval of its COVID-19 vaccine

Pharmaceutical company Pfizer has started its application to the U.S. Food and Drug Administration for full approval of its COVID-19 vaccine. Since December, Pfizer has been authorized on an emergency ...
Hosted on MSN

Moderna, Inc. (MRNA) Withdraws Application for COVID-flu Combination Vaccine

Moderna, Inc. (NASDAQ:MRNA) today announced that it had voluntarily withdrawn the pending Biologics License Application (BLA) seeking approval for its COVID-19 and Influenza combination vaccine for ...
Houston Chronicle

COVID-19 vaccine: Which is the most effective

There are at least 12 vaccines on the market already in application or in the last phases of their clinical trials, waiting to be endorsed by the health authorities of the United States, the European ...
Nasdaq

Ministry of Health, Labour and Welfare in Japan Approves Partial Change Application for Moderna's COVID-19 mRNA Vaccine Targeting SARS-COV-2 Variant JN.1

CAMBRIDGE, MA / ACCESSWIRE / August 23, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that it has received approval from the Ministry of Health, Labour and Welfare (MHLW) in Japan for a partial ...